Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Change in Account Payables (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Change in Account Payables for 2 consecutive years, with $428000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 73.28% to $428000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $152000.0 through Dec 2025, down 90.04% year-over-year, with the annual reading at $152000.0 for FY2025, 90.04% down from the prior year.
  • Change in Account Payables hit $428000.0 in Q4 2025 for Xilio Therapeutics, up from -$1.8 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.1 million in Q2 2025 to a low of -$1.8 million in Q3 2025.